Girón CKI, Huerta LJG

Language: Spanish
References: 30
Page: 15-24
PDF size: 448.08 Kb.

ABSTRACT

Asthma frequently implies an allergic component that provokes an excessive production of IgE when responding to environmental allergens. IgE joins the receptors of the cellular membrane receptors producing the release of the mediators in the inflammation. Allergy develops in the most part due to genetic factors that the patient inherits from his/her parents, as well as due to environmental factors. The treatment is based upon avoiding the triggering factors (allergens), the use of medicines and allergy vaccination (immunotherapy). The medicines are getting better results with a lot fewer adverse reactions, but they have the problem that when being taken out of the treatment, and once their sericeous level has decreased, the protection to the patient also decreases. The allergy vaccines are nowadays an excellent choice. They must be only prepared with standardized allergenic extracts and exclusively directed by an allergist doctor. The molecular basis of its beneficial effect have been known since a considerable time ago and they are summarize in a specific IgE decrease for the allergen against which the patient is being vaccinated, and a decrease in the reactivity of mastocytes and basophiles.

REFERENCES

1. Presta L, Lahar S et al. Humanization of an antibody direct against IgE. Journal of Immunol 1993; 151: 2623-2632.

2. Breedveeld F. Therapeutic monoclonal antibodies. Lancet 2000; 355: 735-740.

3. Vilella R. La respuesta inmunoalergénica mediada por IgE. Arch Bronconeumol 2006; 42 supl 1: 6-12.

4. Berger W, Gupta N et al. Evaluation of long term safety of the anti-IgE antibody, Omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003; 91: 182-188.

5. Milgrom H, Fick R et al. Treatment al allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999; 341: 1966-1973.

6. Clark J, Chian D et al. Omalizumab in the treatment of allergic respiratory disease. Journal of Asthma 2006; 43: 87-93.

7. Humbert M, Beasley R et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-316.

8. Cabrera P. Antiinmunoglobulina E, un anticuerpo monoclonal en el tratamiento de enfermedades respiratorias. Arch Bronconeumol 2006; 42: 241-245.

9. Brownell J, Casale T et al. Anti-IgE therapy. Immunol Allergy Clin N Am 2004; 24: 551-568.

10. Nowak D. Management of asthma with anti-immunoglobulin E: A review of clinical trials of omalizumab. Respir Med 2006; 100: 1907-1917.

11. Boulet L, Chapman K et al. Inhibitory effects of anti-IgE Anti –IgE antibody E25 on Allergen –induced early asthmatic response. Am J Respir Crit Care Med 1997; 155: 1835-1840.

12. Djukanovic R, Wilson S et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Resp and Crit Care Med 2004; 170: 583-593.

13. Holgate S, Bousquet J et al. Efficacy of omalizumab, an antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res and Opin 2001; 14(4): 233-240.

14. Soler M, Matz R et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254-61.

15. Quentin B, Corren J et al. Omalizumab is effective in long-term control of allergic asthma. Ann Allergy Asthma Immunol 2003; 91: 154-159.

16. Oba Y, Salzman G et al. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate to severe allergic asthma. J Allergy Clin Immunol 2004; 114: 265-269.

17. Niebauer K, Dewilde S et al. Impact of omalizumab on quality of life outcomes in patients with moderate to severe allergic asthma. Ann Allergy Immunol 2006; 96: 316-326.

18. Fahy J, Cockcrof D et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Med 1999; 160: 1023-1027.

19. Shulman E. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Med 2001; 164: S6-11.

20. Corren J, Casale T et al. Omalizumab a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003; 111: 87-90.

21. Bosquet J, Cabrera P et al. The effect of treatment with omalizumab, an anti-IgE antibody on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60: 302-308.

22. Huang Y, Leyko B et al. Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells. Ann Allergy Immunol 2005; 95: 443-451.

23. Walker S, Monteil M et al. Anti-IgE para el asma crónica en adultos y niños. Revisión Cochrane 2006.

24. Fernández V et al. Utilidad clínica del omalizumab. Arch Bronconeumol 2006; 42 supl 1: 32-36.

25. Busse W, Corren et al. Omalizumab anti-IgE recombinant humanized monoclonal antibody for treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184-190.

26. Lemanske R, Nayak A et al. Omalizumab improves: Asthma-related quality of life in children with allergic asthma. Pediatrics 2002: 110-155.

27. Dewilde S, Tunk F et al. The economic value of anti-IgE in severe persistent, IgE mediated (allergic) asthma patients adaptation of INNOVATE to Sweden. Curr Med Research and Opin 2006; 22(9): 1765-1776.

28. Chipps B, Buhl R et al. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Resp Opin 2006; 22(11): 2201-2205.

29. Bousquet J, Wenzel S et al. Predicting response to omalizumab an anti-IgE antibody in patients with allergic asthma. Chest 2004; 125: 1378-1386.

30. Chang T, Shiung Y et al. Anti-IgE as a mast cell stabilizing therapeutic agent. J Allergy Clin Immunol 2006; 117: 1203-1212.